Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Exp Med
Huvudupphovsmän: Nicoś, Marcin, Krawczyk, Paweł, Jarosz, Bożena, Sawicki, Marek, Szumiłło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2015
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://ncbi.nlm.nih.gov/pubmed/25902737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk